Cargando…

Impaired Brain Mitochondrial Bioenergetics in the Ts65Dn Mouse Model of Down Syndrome Is Restored by Neonatal Treatment with the Polyphenol 7,8-Dihydroxyflavone

Down syndrome (DS), a major genetic cause of intellectual disability, is characterized by numerous neurodevelopmental defects. Previous in vitro studies highlighted a relationship between bioenergetic dysfunction and reduced neurogenesis in progenitor cells from the Ts65Dn mouse model of DS, suggest...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valenti, Daniela, Stagni, Fiorenza, Emili, Marco, Guidi, Sandra, Bartesaghi, Renata, Vacca, Rosa Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773005/ https://www.ncbi.nlm.nih.gov/pubmed/35052567 http://dx.doi.org/10.3390/antiox11010062

Ejemplares similares

Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome
por: Giacomini, Andrea, et al.
Publicado: (2015)

Timing of Treatment with the Flavonoid 7,8-DHF Critically Impacts on Its Effects on Learning and Memory in the Ts65Dn Mouse
por: Giacomini, Andrea, et al.
Publicado: (2019)

Pharmacotherapy with Fluoxetine Restores Functional Connectivity from the Dentate Gyrus to Field CA3 in the Ts65Dn Mouse Model of Down Syndrome
por: Stagni, Fiorenza, et al.
Publicado: (2013)

Long-term effect of neonatal inhibition of APP gamma-secretase on hippocampal development in the Ts65Dn mouse model of Down syndrome
por: Stagni, Fiorenza, et al.
Publicado: (2017)

The flavonoid 7,8-DHF fosters prenatal brain proliferation potency in a mouse model of Down syndrome
por: Stagni, Fiorenza, et al.
Publicado: (2021)

Pathological trajectory in the Ts65Dn model of Down syndrome
por: Tallino, Savannah, et al.
Publicado: (2023)

Cholinergic Senescence in the Ts65Dn Mouse Model for Down Syndrome
por: Kirstein, Martina, et al.
Publicado: (2022)

Breathing and Oxygen Carrying Capacity in Ts65Dn and Down Syndrome
por: DeRuisseau, Lara R, et al.
Publicado: (2023)

Increased male reproductive success in Ts65Dn “Down syndrome” mice
por: Moore, Clara S., et al.
Publicado: (2010)

Digastric Muscle Phenotypes of the Ts65Dn Mouse Model of Down Syndrome
por: Glass, Tiffany J., et al.
Publicado: (2016)

Rescue of deficits by Brwd1 copy number restoration in the Ts65Dn mouse model of Down syndrome
por: Fulton, Sasha L., et al.
Publicado: (2022)

Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome
por: Simoes de Souza, Fabio M., et al.
Publicado: (2011)

Synaptic Vesicle Recycling Is Unaffected in the Ts65Dn Mouse Model of Down Syndrome
por: Marland, Jamie R. K., et al.
Publicado: (2016)

Hypocellularity in the Murine Model for Down Syndrome Ts65Dn Is Not Affected by Adult Neurogenesis
por: López-Hidalgo, Rosa, et al.
Publicado: (2016)

Luteolin induces hippocampal neurogenesis in the Ts65Dn mouse model of Down syndrome
por: Zhou, Wen-Bo, et al.
Publicado: (2019)

Identification of the translocation breakpoints in the Ts65Dn and Ts1Cje mouse lines: relevance for modeling down syndrome
por: Duchon, Arnaud, et al.
Publicado: (2011)

Deleterious Effects of Chronic Folate Deficiency in the Ts65Dn Mouse Model of Down Syndrome
por: Helm, Susan, et al.
Publicado: (2017)

The Adult Ts65Dn Mouse Model of Down Syndrome Shows Altered Swallow Function
por: Glass, Tiffany J., et al.
Publicado: (2019)

Glutamatergic synaptic deficits in the prefrontal cortex of the Ts65Dn mouse model for Down syndrome
por: Thomazeau, Aurore, et al.
Publicado: (2023)

Targeting APP/AICD in Down syndrome
por: Guidi, Sandra, et al.
Publicado: (2017)

Altered intrinsic and network properties of neocortical neurons in the Ts65Dn mouse model of Down syndrome
por: Cramer, Nathan P., et al.
Publicado: (2015)

Protein Dynamics Associated with Failed and Rescued Learning in the Ts65Dn Mouse Model of Down Syndrome
por: Ahmed, Md. Mahiuddin, et al.
Publicado: (2015)

Phosphoproteomic Alterations of Ionotropic Glutamate Receptors in the Hippocampus of the Ts65Dn Mouse Model of Down Syndrome
por: Gómez de Salazar, Macarena, et al.
Publicado: (2018)

Spatiotemporal development of spinal neuronal and glial populations in the Ts65Dn mouse model of Down syndrome
por: Aziz, Nadine M., et al.
Publicado: (2019)

Signalling pathways contributing to learning and memory deficits in the Ts65Dn mouse model of Down syndrome
por: Freeburn, Aimée, et al.
Publicado: (2021)

Effects of Neonatal Neural Progenitor Cell Implantation on Adult Neuroanatomy and Cognition in the Ts65Dn Model of Down Syndrome
por: Rachubinski, Angela L., et al.
Publicado: (2012)

Longitudinal neuroanatomical and behavioral analyses show phenotypic drift and variability in the Ts65Dn mouse model of Down syndrome
por: Shaw, Patricia R., et al.
Publicado: (2020)

Timing of therapies for Down syndrome: the sooner, the better
por: Stagni, Fiorenza, et al.
Publicado: (2015)

Increased excitability and altered action potential waveform in cerebellar granule neurons of the Ts65Dn mouse model of Down syndrome
por: Usowicz, Maria M., et al.
Publicado: (2012)

Heart rate and blood pressure in male Ts65Dn mice: a model to investigate cardiovascular responses in Down syndrome
por: DeRuisseau, Lara R., et al.
Publicado: (2019)

Evidence of Energy Metabolism Alterations in Cultured Neonatal Astrocytes Derived from the Ts65Dn Mouse Model of Down Syndrome
por: Zampieri, Bruna L., et al.
Publicado: (2022)

Physical Training Chronically Stimulates the Motor Neuron Cell Nucleus in the Ts65Dn Mouse, a Model of Down Syndrome
por: Inguscio, Chiara Rita, et al.
Publicado: (2023)

Monoacylglycerol Lipase Inhibitor JZL184 Improves Behavior and Neural Properties in Ts65Dn Mice, a Model of Down Syndrome
por: Lysenko, Larisa V., et al.
Publicado: (2014)

Pharmacological Modulation of Three Modalities of CA1 Hippocampal Long-Term Potentiation in the Ts65Dn Mouse Model of Down Syndrome
por: Scott-McKean, Jonah J., et al.
Publicado: (2018)

Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
por: Kazim, Syed Faraz, et al.
Publicado: (2017)

Cilostazol, a Phosphodiesterase 3 Inhibitor, Moderately Attenuates Behaviors Depending on Sex in the Ts65Dn Mouse Model of Down Syndrome
por: Tsuji, Masahiro, et al.
Publicado: (2020)

Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome
por: Puente-Bedia, Alba, et al.
Publicado: (2022)

Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome
por: Aziz, Nadine M., et al.
Publicado: (2018)

Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging
por: Duval, Nathan, et al.
Publicado: (2018)

Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice
por: Yin, Xiaomin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_d01j6cjd10ic3ne75gp6fub1cl